The apolipoprotein E gene ε4 allele (APOE4) is the strongest genetic risk factor for Alzheimer’s disease (AD). Over 60% of patients have at least one APOE4 allele. A drug discovery approach targeting aging and AD transcriptomic signatures suggests bumetanide might prevent or treat AD in people with the APOE4/APOE4 genotype.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
DeTure, M. A. & Dickson, D. W. Mol. Neurodegener. 14, 32 (2019).
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C. C. & Bu, G. Nat. Rev. Neurol. 15, 501–518 (2019).
Taubes, A. et al. Nat. Aging https://doi.org/10.1038/s43587-021-00122-7 (2021).
Zhao, N. et al. Neuron 106, 727–742.e6 (2020).
Tully, P. J., Hanon, O., Cosh, S. & Tzourio, C. J. Hypertens. 34, 1027–1035 (2016).
Soul, J. S. et al. Ann. Neurol. 89, 327–340 (2021).
Sprengers, J. J. et al. J. Am. Acad. Child Adolesc. Psychiatry 60, 865–876 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Li, Z., Zhao, N. A water pill against Alzheimer’s disease. Nat Aging 1, 868–869 (2021). https://doi.org/10.1038/s43587-021-00124-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43587-021-00124-5
